PL374364A1 - Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania - Google Patents

Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania

Info

Publication number
PL374364A1
PL374364A1 PL03374364A PL37436403A PL374364A1 PL 374364 A1 PL374364 A1 PL 374364A1 PL 03374364 A PL03374364 A PL 03374364A PL 37436403 A PL37436403 A PL 37436403A PL 374364 A1 PL374364 A1 PL 374364A1
Authority
PL
Poland
Prior art keywords
inhibitors
well
coa reductase
antihypertensive agents
hmg coa
Prior art date
Application number
PL03374364A
Other languages
English (en)
Inventor
Roger Benjamin Ruggeri
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of PL374364A1 publication Critical patent/PL374364A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL03374364A 2002-07-02 2003-06-20 Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania PL374364A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39371502P 2002-07-02 2002-07-02

Publications (1)

Publication Number Publication Date
PL374364A1 true PL374364A1 (pl) 2005-10-17

Family

ID=30115632

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03374364A PL374364A1 (pl) 2002-07-02 2003-06-20 Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania

Country Status (12)

Country Link
US (2) US7071210B2 (pl)
EP (1) EP1519752A1 (pl)
JP (1) JP2005538977A (pl)
CN (1) CN1665536A (pl)
AU (1) AU2003238622A1 (pl)
BR (1) BR0312334A (pl)
CA (1) CA2490988A1 (pl)
MX (1) MXPA05000261A (pl)
PL (1) PL374364A1 (pl)
TW (1) TW200406221A (pl)
WO (1) WO2004004777A1 (pl)
ZA (1) ZA200410212B (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
PT1603553E (pt) * 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
WO2004082675A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of s-[2- ([[1- (2-ethylbutyl) cyclohexyl] carbonyl] amino) phenyl] 2-methylpropanethioate
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
RS20060018A (sr) 2003-07-14 2007-12-31 Arena Pharmaceuticals Inc., Derivati spojenih arila i heteroarila kao modulatori metabolizma u profilaksi i lečenju sa njima povezanih stanja
WO2005033082A2 (en) * 2003-09-30 2005-04-14 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
WO2005117869A1 (en) * 2004-05-12 2005-12-15 Sepracor Inc. Combinations comprising (s)-amlodipine and a cholesteryl ester transfer protein inhibitor, and methods for reducing hypertension
US20060020036A1 (en) * 2004-06-24 2006-01-26 Luc Van Rompaey Methods and compositions to promote bone homestasis
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CA2605214C (en) 2004-12-31 2016-07-12 Reddy Us Therapeutics, Inc. Benzylamine derivatives as cetp inhibitors
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
KR101436644B1 (ko) * 2006-01-31 2014-09-01 코와 가부시키가이샤 당뇨병 치료제
WO2007107843A1 (en) * 2006-03-22 2007-09-27 Pfizer Products Inc. Methods of treatment with cetp inhibitors
EP2034998A1 (en) * 2006-05-11 2009-03-18 Janssen Pharmaceutica, N.V. 1,2,3,4-tetrahydro-quinoline derivatives as cetp inhibitors
TW200848021A (en) 2007-03-06 2008-12-16 Wyeth Corp Sulfonylated heterocycles useful for modulation of the progesterone receptor
EP3323818A1 (en) 2010-09-22 2018-05-23 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
EP2744803A2 (en) 2011-08-18 2014-06-25 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (cetp) inhibitors
MX352074B (es) 2011-09-27 2017-11-08 Dr Reddys Laboratories Ltd Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
JP6030147B2 (ja) 2011-11-30 2016-11-24 デウン ファーマシューティカル カンパニー リミテッド 高トリグリセリド血症または高トリグリセリド血症に関連する疾患を予防または治療するための医薬組成物
WO2014004987A2 (en) * 2012-06-30 2014-01-03 Hellstrom Harold R Short-term infarction-based test for investigative drugs
PL3242666T3 (pl) 2015-01-06 2025-02-17 Arena Pharmaceuticals, Inc. Związek do zastosowania w leczeniu dolegliwości związanych z receptorem s1p1
BR112017027656B1 (pt) 2015-06-22 2023-12-05 Arena Pharmaceuticals, Inc. Hábito cristalino de placa livre de sal de l-arginina de ácido (r)-2-(7-(4- ciclopentil-3-(trifluorometil)benzilóxi)- 1,2,3,4-tetra-hidrociclo-penta[b]indol-3- il)acético, composição farmacêutica que o compreende, seus usos e método de preparação do mesmo
MX2019009841A (es) 2017-02-16 2020-01-30 Arena Pharm Inc Compuestos y metodos para el tratamiento de la colangitis biliar primaria.
CA3102136A1 (en) 2018-06-06 2019-12-12 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714274D0 (en) * 1997-07-08 1997-09-10 Zeneca Ltd Pharmaceutical composition
AP1207A (en) * 1997-08-29 2003-09-20 Pfizer Prod Inc Combination therapy.
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
EP1180102B9 (en) * 1999-05-27 2005-03-02 Pfizer Products Inc. Mutual prodrugs of amlodipine and atorvastatin
HN2000000050A (es) * 1999-05-27 2001-02-02 Pfizer Prod Inc Sal mutua de amlodipino y atorvastatina
EP1125579A3 (en) * 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
US20030092745A1 (en) * 2000-02-25 2003-05-15 Pfizer Inc. Combination therapy
US6812345B2 (en) * 2000-06-15 2004-11-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
CZ2003390A3 (en) * 2000-08-15 2004-03-17 Pfizer Products Inc. Therapeutic combination of a cetp inhibitor and atorvastatin
WO2002030400A1 (fr) * 2000-10-06 2002-04-18 Takeda Chemical Industries, Ltd. Preparations solides
JP4284017B2 (ja) * 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
US6737430B2 (en) * 2000-11-09 2004-05-18 Pfizer, Inc. Mutual prodrug of amlodipine and atorvastatin
KR20030061444A (ko) * 2000-12-13 2003-07-18 시오노기세이야쿠가부시키가이샤 항고지혈증제
JP2001288115A (ja) * 2001-02-07 2001-10-16 Yamanouchi Pharmaceut Co Ltd 下部尿路症治療剤
US20030064967A1 (en) 2001-04-11 2003-04-03 Jayraz Luchoomun Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US6956627B2 (en) * 2002-09-10 2005-10-18 Au Optronics Corp. Electronic apparatus with liquid crystal display, digitizer, and housing, fastened by screws

Also Published As

Publication number Publication date
US20060128751A1 (en) 2006-06-15
AU2003238622A1 (en) 2004-01-23
TW200406221A (en) 2004-05-01
ZA200410212B (en) 2006-04-26
US7071210B2 (en) 2006-07-04
WO2004004777A1 (en) 2004-01-15
EP1519752A1 (en) 2005-04-06
CA2490988A1 (en) 2004-01-15
JP2005538977A (ja) 2005-12-22
US20040039018A1 (en) 2004-02-26
MXPA05000261A (es) 2005-04-11
BR0312334A (pt) 2005-04-12
CN1665536A (zh) 2005-09-07

Similar Documents

Publication Publication Date Title
IL165328A0 (en) Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents
PL374364A1 (pl) Inhibitory CETP w kombinacji ze środkami przeciw nadciśnieniu i ich zastosowania
AU2003217870A8 (en) Pini-modulating compounds and methods of use thereof
AU2003303128A8 (en) Inhibitors and methods of use thereof
PL368637A1 (pl) Związki heterocykliczne i sposoby ich zastosowania
PL376575A1 (pl) Podstawione związki heterocykliczne oraz sposoby wykorzystania
IL159588A0 (en) Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
ZA200500680B (en) Quinoline derivatives and their use as mycrobacterial inhibitors
IL163929A0 (en) Combination comprising an hmg-coa reductase inhibitor and an insulin secretor enhancer or an insulinsensitizer
AU2003225668A1 (en) Pin1-modulating compounds and methods of use thereof
EP1549614A4 (en) VASCULATORY AGENTS AND METHODS FOR THEIR APPLICATION
AU2003213673A1 (en) Pin1-modulating compounds and methods of use thereof
AU2003259735A8 (en) Small-mer compositions and methods of use
IL173936A0 (en) Heterocyclic inhibitors of mek and methods of use thereof
PL375586A1 (pl) Podstawione pochodne amidu kwasu antranilowego oraz sposoby wykorzystania
AU2003281324A8 (en) Antisense modulation of hmg-coa reductase expression
IL157659A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
EP1549316A4 (en) HAMMER OF TFGbeta
EP1684754A4 (en) HMG COA REDUCTASE INHIBITORS AND METHOD
ZA200501381B (en) New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
AU2003299441A8 (en) Nf-hev compositions and methods of use
PL371217A1 (pl) Inhibitory integryny alfaVbeta6
PL374581A1 (pl) Diaminotiazole przydatne jako selektywne inhibitory CDK4
AU2002306624A1 (en) Heterocyclic analgesic compounds and methods of use thereof
AU2003275056A8 (en) Novel lapacho compounds and methods of use thereof

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)